SEC Form 4 · accession 0001192482-18-000023
Recro Pharma, Inc. · REPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Randall Mack
Officer — Senior VP, Development
Period of report
Jan 2, 2018
Accepted (ET)
Jan 4, 2018 · 8:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001588972
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 2, 2018 | A | 11,500 | $0.00 | A | 31,613 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $9.04 | Jan 2, 2018 | A | 23,000 | A | — | Jan 2, 2028 | Common Stock | 23,000 | 23,000 | D |
Explanation of responses
- F1All shares of common stock are represented by restricted stock units that will vest in four equal installments beginning January 2, 2019, subject to continued employment with the Company. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.
- F2The stock option vests in equal monthly installments over 48 months, beginning on the date that is one month from the date of grant, subject to continued employment with the Company.